If you currently take Somatuline Depot for acromegaly you already know how effective, safe, and generally well-tolerated it is.
Maybe you have questions you forgot to ask your healthcare professional when you started taking Somatuline Depot. Perhaps you're curious about how long acromegaly therapy typically lasts. Or you're interested in possible side effects.
Learn more about acromegaly therapy and how long it typically lasts.
Know which side effects to expect and what to do if they appear.
Find out how easy it is to inject Somatuline Depot into the body to control acromegaly.
Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.
Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline® Depot may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.
Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline® Depot 60mg.
There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline® Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.
Somatuline® Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.
Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline® Depot may reduce the intestinal absorption of co-administered drugs. Caution should be used.
The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.
Please see Full Prescribing
Information for additional important information.
SOMATULINE® DEPOT IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).
THIS WEB SITE IS INTENDED FOR US RESIDENTS ONLY. ®TERCICA, INC. ALL RIGHTS RESERVED.
2008 Tercica Legal Notices | Privacy Statement
